Patrick D. Beauchesne

CHU Nancy
Nancy, FR 
CHU Nancy
Nancy, FR 

Overview

Patrick Beauchesne practices practicing medicine in Nancy, France.

His clinical expertise encompasses Glioma, Gliomatosis Cerebri, Glioblastoma, and Astrocytoma.

He is actively involved in clinical research, co-authoring 24 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

CHU Nancy
Nancy, France
Other Locations
Lyon, France
Saint-etienne-de-valoux, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: Intensified Protocol, Stupp Protocol
Study Phase: Phase 3
Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study
Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study
Enrollment Status: Terminated
Publish Date: February 09, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
View 1 Less Clinical Trial

24 Total Publications

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 31, 2019

Frequently Asked Questions about Patrick D. Beauchesne

Is Patrick D. Beauchesne a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Patrick D. Beauchesne is classified as an Experienced expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Patrick D. Beauchesne participate in research or clinical trials?

Yes. Patrick D. Beauchesne has published 24 articles and abstracts on conditions like Glioma. You can view a list of Patrick D. Beauchesne's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Beauchesne's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile